دورية أكاديمية
Sex differences in associations between APOE ε2 and longitudinal cognitive decline.
| العنوان: | Sex differences in associations between APOE ε2 and longitudinal cognitive decline. |
|---|---|
| المؤلفون: | Wood ME; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada., Xiong LY; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Wong YY; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Buckley RF; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Florey Institute, University of Melbourne, Parkville, Victoria, Australia.; Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia., Swardfager W; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Masellis M; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Lim ASP; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Nichols E; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Joie R; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA., Casaletto KB; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, California, USA., Kumar RG; Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Dams-O'Connor K; Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Palta P; Departments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, New York, USA., George KM; Department of Public Health Sciences, University of California Davis School of Medicine, Davis, California, USA., Satizabal CL; Department of Population Health Science and Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, Texas, USA.; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA., Barnes LL; Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA., Schneider JA; Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA., Binet AP; Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden., Villeneuve S; Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada.; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.; McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada., Pa J; Mark and Mary Stevens Neuroimaging and Informatics Institute, Department of Neurology, University of Southern California, Los Angeles, California, USA., Brickman AM; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA., Black SE; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Rabin JS; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.; Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada.; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.; Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. |
| مؤلفون مشاركون: | ADNI and Prevent-AD Research Groups |
| المصدر: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Oct; Vol. 19 (10), pp. 4651-4661. Date of Electronic Publication: 2023 Mar 30. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : Hoboken, NJ : John Wiley & Sons, Ltd. Original Publication: Orlando, FL : Elsevier, Inc. |
| مواضيع طبية MeSH: | Apolipoprotein E2*/genetics , Cognitive Dysfunction*/genetics , Sex Characteristics*, Adult ; Female ; Humans ; Male ; Apolipoprotein E3/genetics ; Apolipoproteins E/genetics ; Genotype |
| مستخلص: | Introduction: We examined whether sex modifies the association between APOE ε2 and cognitive decline in two independent samples. Methods: We used observational data from cognitively unimpaired non-Hispanic White (NHW) and non-Hispanic Black (NHB) adults. Linear mixed models examined interactive associations of APOE genotype (ε2 or ε4 carrier vs. ε3/ε3) and sex on cognitive decline in NHW and NHB participants separately. Results: In both Sample 1 (N = 9766) and Sample 2 (N = 915), sex modified the association between APOE ε2 and cognitive decline in NHW participants. Specifically, relative to APOE ε3/ε3, APOE ε2 protected against cognitive decline in men but not women. Among APOE ε2 carriers, men had slower decline than women. Among APOE ε3/ε3 carriers, cognitive trajectories did not differ between sexes. There were no sex-specific associations of APOE ε2 with cognition in NHB participants (N = 2010). Discussion: In NHW adults, APOE ε2 may protect men but not women against cognitive decline. Highlights: We studied sex-specific apolipoprotein E (APOE) ε2 effects on cognitive decline. In non-Hispanic White (NHW) adults, APOE ε2 selectively protects men against decline. Among men, APOE ε2 was more protective than APOE ε3/ε3. In women, APOE ε2 was no more protective than APOE ε3/ε3. Among APOE ε2 carriers, men had slower decline than women. There were no sex-specific APOE ε2 effects in non-Hispanic Black (NHB) adults. (© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.) |
| References: | Chêne G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimers Dement J Alzheimers Assoc. 2015;11(3):310-320. doi:10.1016/j.jalz.2013.10.005. Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 1997;49(6):1498-1504. doi:10.1212/wnl.49.6.1498. Shaw C, Hayes-Larson E, Glymour MM, et al. Evaluation of selective survival and sex/gender differences in dementia incidence using a simulation model. JAMA Netw Open. 2021;4(3):e211001. doi:10.1001/jamanetworkopen.2021.1001. Nebel RA, Aggarwal NT, Barnes LL, et al. Understanding the impact of sex and gender in Alzheimer's disease: a call to action. Alzheimers Dement. 2018;14(9):1171-1183. doi:10.1016/j.jalz.2018.04.008. Buckley RF, Mormino EC, Amariglio RE, et al. Sex, amyloid, and APOEε4 and risk of cognitive decline in preclinical Alzheimer's disease: findings from three well-characterized cohorts. Alzheimers Dement J Alzheimers Assoc. 2018;14(9):1193-1203. doi:10.1016/j.jalz.2018.04.010. Edwards L, La Joie R, Iaccarino L, et al. Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiol Aging. 2021;105:86-98. doi:10.1016/j.neurobiolaging.2021.04.003. Liesinger AM, Graff-Radford NR, Duara R, et al. Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. Acta Neuropathol (Berl). 2018;136(6):873-885. doi:10.1007/s00401-018-1908-x. Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer's disease and common neuropathologies of aging. Acta Neuropathol (Berl). 2018;136(6):887-900. doi:10.1007/s00401-018-1920-1. Palta P, Rippon B, Tahmi M, et al. Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults. Neurobiol Aging. 2021;103:109-116. doi:10.1016/j.neurobiolaging.2021.03.007. Snyder HM, Asthana S, Bain L, et al. Sex biology contributions to vulnerability to Alzheimer's disease: a think tank convened by the Women's Alzheimer's Research Initiative. Alzheimers Dement. 2016;12(11):1186-1196. doi:10.1016/j.jalz.2016.08.004. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol. 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263. Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006;33(3):279-308. doi:10.1080/03014460600594513. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17-23. doi:10.1038/ng1934. Rubin L, Ingram LA, Resciniti NV, et al. Genetic Risk Factors for Alzheimer's disease in racial/ethnic minority populations in the U.S.: a scoping review. Front Public Health. 2021;9:784958. doi:10.3389/fpubh.2021.784958. Farrer LA. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349-1356. doi:10.1001/jama.278.16.1349. Altmann A, Tian L, Henderson VW, Greicius MD. Alzheimer's Disease Neuroimaging Initiative Investigators. Sex modifies the APOE-related risk of developing Alzheimer disease: sex and APOE -Related AD Risk. Ann Neurol. 2014;75(4):563-573. doi:10.1002/ana.24135. Neu SC, Pa J, Kukull W, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer's disease. JAMA Neurol. 2017;74(10):1178-1189. doi:10.1001/jamaneurol.2017.2188. Lamonja-Vicente N, Dacosta-Aguayo R, López-Olóriz J, et al. Sex-specific protective effects of APOE ε2 on cognitive performance. J Gerontol Ser A. 2021;76(1):41-49. doi:10.1093/gerona/glaa247. Beydoun MA, Weiss J, Beydoun HA, et al. Race, APOE genotypes, and cognitive decline among middle-aged urban adults. Alzheimers Res Ther. 2021;13(1):120. doi:10.1186/s13195-021-00855-y. Qiu C, Kivipelto M, Agüero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry. 2004;75(6):828-833. doi:10.1136/jnnp.2003.021493. Hellwege J, Keaton J, Giri A, Gao X, Velez Edwards DR, Edwards TL. Population stratification in genetic association studies. Curr Protoc Hum Genet. 2017;95:1.22.1-1.22.23. doi:10.1002/cphg.48. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet Lond Engl. 2003;361(9357):598-604. doi:10.1016/S0140-6736(03)12520-2. Liu XQ, Paterson AD, John EM, Knight JA. The role of self-defined race/ethnicity in population structure control. Ann Hum Genet. 2006;70(Pt 4):496-505. doi:10.1111/j.1469-1809.2005.00255.x. Qin W, Li W, Wang Q, et al. Race-related association between APOE genotype and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2021;83(2):897-906. doi:10.3233/JAD-210549. Weuve J, Barnes LL, Mendes de Leon CF, et al. Cognitive aging in Black and White Americans: cognition, cognitive decline, and incidence of Alzheimer disease dementia. Epidemiol Camb Mass. 2018;29(1):151-159. doi:10.1097/EDE.0000000000000747. Griswold AJ, Celis K, Bussies PL, et al. Increased APOE ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds. Alzheimers Dement. 2021;17(7):1179-1188. doi:10.1002/alz.12287. Suri S, Heise V, Trachtenberg AJ, Mackay CE. The forgotten APOE allele: a review of the evidence and suggested mechanisms for the protective effect of APOE ɛ2. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2878-2886. doi:10.1016/j.neubiorev.2013.10.010. National Alzheimer's Coordinating Center. NACC Uniform Data Set initial visit packet version 3.0. Published online 2015. Bennett DA, Schneider JA, Aggarwal NT, et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27(3):169-176. doi:10.1159/000096129. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198-205. doi:10.1212/wnl.59.2.198. Petersen RC, Aisen PS, Beckett LA, et al>. Tremblay-Mercier J, Madjar C, Das S, et al. Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. NeuroImage Clin. 2021;31:102733. doi:10.1016/j.nicl.2021.102733. Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N. The essentiality of reporting Hardy-Weinberg Equilibrium calculations in population-based genetic association studies. Cell J. 2015;17(2):187-192. doi:10.22074/cellj.2016.3711. Buckley RF, Scott MR, Jacobs HIL, et al. Sex mediates relationships between regional tau pathology and cognitive decline. Ann Neurol. 2020;88(5):921-932. doi:10.1002/ana.25878. Vivot A, Power MC, Glymour MM, et al. Jump, hop, or skip: modeling practice effects in studies of determinants of cognitive change in older adults. Am J Epidemiol. 2016;183(4):302-314. doi:10.1093/aje/kwv212. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496. Rabin JS, Schultz AP, Hedden T, et al. Interactive associations of vascular risk and β-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018;75(9):1124-1131. doi:10.1001/jamaneurol.2018.1123. Rabin JS, Nichols E, La Joie R, et al. Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain. 2022:145(8):2823-2833. doi:10.1093/brain/awac178. Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of Alzheimer's disease. J Steroid Biochem Mol Biol. 2016;160:134-147. doi:10.1016/j.jsbmb.2016.03.012. Gamache J, Yun Y, Chiba-Falek O. Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders. Dis Model Mech. 2020;13(8):dmm045211. doi:10.1242/dmm.045211. Ratnakumar A, Zimmerman SE, Jordan BA, Mar JC. Estrogen activates Alzheimer's disease genes. Alzheimers Dement Transl Res Clin Interv. 2019;5:906-917. doi:10.1016/j.trci.2019.09.004. Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nat Rev Endocrinol. 2015;11(7):393-405. doi:10.1038/nrendo.2015.82. Mosconi L, Berti V, Quinn C, et al. Sex differences in Alzheimer risk. Neurology. 2017;89(13):1382-1390. doi:10.1212/WNL.0000000000004425. Hohman TJ, Dumitrescu L, Barnes LL, et al. Sex-specific association of Apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75(8):989-998. doi:10.1001/jamaneurol.2018.0821. Fleisher A, Grundman M, Jr JackCR, et al. Sex, Apolipoprotein E ε4 status, and hippocampal volume in Mild Cognitive Impairment. Arch Neurol. 2005;62(6):953-957. doi:10.1001/archneur.62.6.953. Barnes LL, Leurgans S, Aggarwal NT, et al. Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology. 2015;85(6):528-534. doi:10.1212/WNL.0000000000001834. Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264-273. doi:10.1001/jamaneurol.2018.4249. Deters KD, Napolioni V, Sperling RA, et al. Amyloid PET imaging in self-identified non-Hispanic Black participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study. Neurology. 2021;96(11):e1491-e1500. doi:10.1212/WNL.0000000000011599. Blue EE, Horimoto ARVR, Mukherjee S, Wijsman EM, Thornton TA. Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics. Alzheimers Dement J Alzheimers Assoc. 2019;15(12):1524-1532. doi:10.1016/j.jalz.2019.07.016. Blair CK, Folsom AR, Knopman DS, et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology. 2005;64(2):268-276. doi:10.1212/01.WNL.0000149643.91367.8A. Rajan KB, Barnes LL, Wilson RS, Weuve J, McAninch EA, Evans DA. Apolipoprotein E genotypes, age, race, and cognitive decline in a population sample. J Am Geriatr Soc. 2019;67(4):734-740. doi:10.1111/jgs.15727. Eissman JM, Dumitrescu L, Mahoney ER, et al. Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. Brain J Neurol. 2022;145(7):2541-2554. doi:10.1093/brain/awac177. Martins C a R, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65(12):1888-1893. doi:10.1212/01.wnl.0000188871.74093.12. Wilson RS. The apolipoprotein E epsilon2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry. 2002;73(6):672-677. doi:10.1136/jnnp.73.6.672. |
| معلومات مُعتمدة: | RF1 AG054617 United States AG NIA NIH HHS; R00 AG061238 United States AG NIA NIH HHS; P50 AG016573 United States AG NIA NIH HHS; P50 AG047266 United States AG NIA NIH HHS; P30 AG010161 United States AG NIA NIH HHS; P30 AG010129 United States AG NIA NIH HHS; P50 AG033514 United States AG NIA NIH HHS; R01 AG015819 United States AG NIA NIH HHS; P30 AG013854 United States AG NIA NIH HHS; P30 AG053760 United States AG NIA NIH HHS; P20 AG068082 United States AG NIA NIH HHS; P30 AG072975 United States AG NIA NIH HHS; P30 AG010124 United States AG NIA NIH HHS; P50 AG023501 United States AG NIA NIH HHS; R01 NS017950 United States NS NINDS NIH HHS; UF1 NS125513 United States NS NINDS NIH HHS; R01 AG071638 United States AG NIA NIH HHS; P50 AG005142 United States AG NIA NIH HHS; T32 AG000247 United States AG NIA NIH HHS; P20 AG068053 United States AG NIA NIH HHS; P50 AG005131 United States AG NIA NIH HHS; P30 AG010133 United States AG NIA NIH HHS; P50 AG016574 United States AG NIA NIH HHS; P50 AG005146 United States AG NIA NIH HHS; U24 AG072122 United States AG NIA NIH HHS; R01 AG052488 United States AG NIA NIH HHS; P30 AG035982 United States AG NIA NIH HHS; P50 AG008702 United States AG NIA NIH HHS; P30 AG008051 United States AG NIA NIH HHS; P50 AG005681 United States AG NIA NIH HHS; P30 AG013846 United States AG NIA NIH HHS; R01 AG017917 United States AG NIA NIH HHS; P50 AG047270 United States AG NIA NIH HHS; RF1 AG070436 United States AG NIA NIH HHS; P50 AG005136 United States AG NIA NIH HHS; P30 AG049638 United States AG NIA NIH HHS; P30 AG012300 United States AG NIA NIH HHS; P50 AG005134 United States AG NIA NIH HHS; P30 AG008017 United States AG NIA NIH HHS; P50 AG025688 United States AG NIA NIH HHS; K99 AG061238 United States AG NIA NIH HHS; R01 AG059727 United States AG NIA NIH HHS; P50 AG005133 United States AG NIA NIH HHS; R01 AG072475 United States AG NIA NIH HHS; P30 AG066509 United States AG NIA NIH HHS; K99 AG065501 United States AG NIA NIH HHS; P20 AG068077 United States AG NIA NIH HHS; P30 AG066546 United States AG NIA NIH HHS; P50 AG005138 United States AG NIA NIH HHS; R01 AG022018 United States AG NIA NIH HHS; P50 AG047366 United States AG NIA NIH HHS; P20 AG068024 United States AG NIA NIH HHS; P30 AG072958 United States AG NIA NIH HHS; P30 AG019610 United States AG NIA NIH HHS; P30 AG072947 United States AG NIA NIH HHS; P30 AG072959 United States AG NIA NIH HHS; P30 AG028383 United States AG NIA NIH HHS |
| فهرسة مساهمة: | Keywords: APOE; Alzheimer's disease; cognitive decline; race/ethnicity; sex differences |
| المشرفين على المادة: | 0 (Apolipoprotein E2) 0 (Apolipoprotein E3) 0 (Apolipoproteins E) 0 (ApoE protein, human) |
| تواريخ الأحداث: | Date Created: 20230330 Date Completed: 20231101 Latest Revision: 20240604 |
| رمز التحديث: | 20240604 |
| مُعرف محوري في PubMed: | PMC10544702 |
| DOI: | 10.1002/alz.13036 |
| PMID: | 36994910 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1552-5279 |
|---|---|
| DOI: | 10.1002/alz.13036 |